Meeting
2019 ASCO Annual Meeting
Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy (SBRT) to treat metastatic anaplastic thyroid cancer (ATC).
Authors
Eric Jeffrey Sherman
Memorial Sloan Kettering Cancer Center, New York, NY
Eric Jeffrey Sherman , C. Jillian Tsai , Wanqing Iris Zhi , James Vincent Fetten , Vanessa Wu , Alan Loh Ho , Nadeem Riaz , David G. Pfister , Nancy Y. Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT03122496
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6088)
DOI
10.1200/JCO.2019.37.15_suppl.6088
Abstract #
6088
Poster Bd #
77
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.
First Author: Marwan Fakih
Poster
2016 Gastrointestinal Cancers Symposium
A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer.
First Author: Austin G. Duffy
Poster
2019 ASCO Annual Meeting
DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.
First Author: Enrique Grande
Poster
2019 ASCO Annual Meeting
A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).
First Author: Taofeek Kunle Owonikoko